PLoS ONE (Jan 2021)

Polygenic risk score validation using Korean genomes of 265 early-onset acute myocardial infarction patients and 636 healthy controls.

  • Youngjune Bhak,
  • Yeonsu Jeon,
  • Sungwon Jeon,
  • Changhan Yoon,
  • Min Kim,
  • Asta Blazyte,
  • Yeonkyung Kim,
  • Younghui Kang,
  • Changjae Kim,
  • Sang Yeub Lee,
  • Jang-Whan Bae,
  • Weon Kim,
  • Yeo Jin Kim,
  • Jungae Shim,
  • Nayeong Kim,
  • Sung Chun,
  • Byoung-Chul Kim,
  • Byung Chul Kim,
  • Semin Lee,
  • Jong Bhak,
  • Eun-Seok Shin

DOI
https://doi.org/10.1371/journal.pone.0246538
Journal volume & issue
Vol. 16, no. 2
p. e0246538

Abstract

Read online

BackgroundThe polygenic risk score (PRS) developed for coronary artery disease (CAD) is known to be effective for classifying patients with CAD and predicting subsequent events. However, the PRS was developed mainly based on the analysis of Caucasian genomes and has not been validated for East Asians. We aimed to evaluate the PRS in the genomes of Korean early-onset AMI patients (n = 265, age ≤50 years) following PCI and controls (n = 636) to examine whether the PRS improves risk prediction beyond conventional risk factors.ResultsThe odds ratio of the PRS was 1.83 (95% confidence interval [CI]: 1.69-1.99) for early-onset AMI patients compared with the controls. For the classification of patients, the area under the curve (AUC) for the combined model with the six conventional risk factors (diabetes mellitus, family history of CAD, hypertension, body mass index, hypercholesterolemia, and current smoking) and PRS was 0.92 (95% CI: 0.90-0.94) while that for the six conventional risk factors was 0.91 (95% CI: 0.85-0.93). Although the AUC for PRS alone was 0.65 (95% CI: 0.61-0.69), adding the PRS to the six conventional risk factors significantly improved the accuracy of the prediction model (P = 0.015). Patients with the upper 50% of PRS showed a higher frequency of repeat revascularization (hazard ratio = 2.19, 95% CI: 1.47-3.26) than the others.ConclusionsThe PRS using 265 early-onset AMI genomes showed improvement in the identification of patients in the Korean population and showed potential for genomic screening in early life to complement conventional risk prediction.